Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

ClinicalTrials.gov ID: NCT04269395

Public ClinicalTrials.gov record NCT04269395. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Multicenter, Long-term Follow-up Study to Assess Recurrence of Actinic Keratosis in Subjects Treated With Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) or Vehicle Cream in the Treatment of Thin and Moderately Thick, Non-hyperkeratotic, Non-pigmented Actinic Keratosis of the Face and Scalp When Using Daylight Photodynamic Therapy (DL-PDT), for Subjects Achieving Complete Response of Treated Lesions at Final Visit in Study RD.06.SPR.112199

Study identification

NCT ID
NCT04269395
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Galderma R&D
Industry
Enrollment
125 participants

Conditions and interventions

Interventions

  • MAL Cream Drug
  • Vehicle cream Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 6, 2020
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021
Last update posted
Oct 9, 2023

2020 – 2021

United States locations

U.S. sites
52
U.S. states
27
U.S. cities
46
Facility City State ZIP Site status
Galderma Investigational Site (Site#8447) Fort Smith Arkansas 72916
Galderma Investigational Site (Site#8577) Encinitas California 92024
Galderma Investigational Site (Site#8636) Fountain Valley California 92708
Galderma Investigational Site (Site#8224) Fremont California 94538
Galderma Investigational Site (Site#8778) Denver Colorado 80210
Galderma Investigational Site (Site#8440) Greenwood Village Colorado 80111
Galderma Investigational Site (Site#8479) Bradenton Florida 34209
Galderma Investigational Site (Site#8769) Lake Worth Florida 33461
Galderma Investigational Site (8770) Lehigh Acres Florida 33936
Galderma Investigational Site (Site#8765) North Miami Beach Florida 33162
Galderma Investigational Site (Site#8734) Pembroke Pines Florida 33028
Galderma Investigational Site (Site#8529) Sanford Florida 32771
Galderma Investigational Site (Site#8126) West Palm Beach Florida 33401
Galderma Investigational Site (Site#8667) Columbus Georgia 31904
Galderma Investigational Site (Site#8755) Boise Idaho 83704
Galderma Investigational Site Boise Idaho 83713
Galderma Investigational Site (Site#8838) Darien Illinois 60561
Galderma Investigational Site (Site#8724) Louisville Kentucky 40241
Galderma Investigational Site (Site#8208) Beverly Massachusetts 01915
Galderma Investigational Site (Site#8574) Clarkston Michigan 48346
Galderma Investigational Site (Site#8757) Saint Joseph Michigan 49085
Galderma Investigational Site Edina Minnesota 55410
Galderma Investigational Site St Louis Missouri 63141
Galderma Investigational Site (Site#8048) Omaha Nebraska 68144
Galderma Investigational Site 9Site#8420) Portsmouth New Hampshire 03801
Galderma Investigational Site (Site#8759) Albuquerque New Mexico 87102
Galderma Investigational Site Brooklyn New York 11209
Galderma Investigational Site New York New York 10010
Galderma Investigational Site New York New York 10022
Galderma Investigational Site New York New York 10029-6501
Galderma Investigational Site New York New York 10075
Galderma Investigational Site (Site#8566) Charlotte North Carolina 28277
Galderma Investigational Site (Site#8595) Dublin Ohio 43016
Galderma Investigational Site (Site#8212) Portland Oregon 97210
Galderma Investigational Site Philadelphia Pennsylvania 19103
Galderma Investigational Site Pittsburgh Pennsylvania 15213
Galderma Investigational Site Sugarloaf Pennsylvania 18249
Galderma Investigational Site (Site#8777) Charleston South Carolina 29407
Galderma Investigational Site (Site#8207) Nashville Tennessee 37215
Galderma Investigational Site (Site#8076) Austin Texas 78759
Galderma Investigational Site (Site#8139) College Station Texas 77845
Galderma Investigational Site (Site#8664) Frisco Texas 75034
Galderma Investigational Site (Site#8576) Houston Texas 77056
Galderma Investigational Site (Site#8546) Pflugerville Texas 78660
Galderma Investigational Site (Site#8761) Salt Lake City Utah 84101
Galderma Investigational Site (Site#8672) Salt Lake City Utah 84117
Galderma Investigational Site (Site#8776) St. George Utah 84790
Galderma Investigational Site (Site#8057) Lynchburg Virginia 24501
Galderma Investigational Site (Site#8779) Seattle Washington 98168
Galderma Investigational Site (Site#8760) Spokane Washington 99202
Galderma Investigational Site 2(Site#8039) Spokane Washington 99202
Galderma Investigational Site (Site#8725) Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04269395, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 9, 2023 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04269395 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →